NEW YORK (GenomeWeb) – MRM and Biodesix said today that they are partnering to develop mass spectrometry-based assays for lung cancer.

Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI technologies to develop blood-based tests for lung cancer.

MRM's iMALDI method uses upfront enrichment of target proteins followed by MALDI mass spec analysis of those proteins.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.